AveXis, Inc. (AVXS) Insider Sells $1,420,950.00 in Stock
AveXis, Inc. (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $94.73, for a total value of $1,420,950.00. Following the completion of the sale, the insider now owns 1,826,502 shares of the company’s stock, valued at $173,024,534.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
AveXis, Inc. (NASDAQ AVXS) traded down $0.34 during trading on Tuesday, hitting $93.50. The stock had a trading volume of 350,535 shares, compared to its average volume of 426,264. AveXis, Inc. has a 52 week low of $44.68 and a 52 week high of $108.27.
AveXis (NASDAQ:AVXS) last posted its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the business posted ($0.87) earnings per share. equities research analysts predict that AveXis, Inc. will post -6.23 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on AVXS shares. Nomura started coverage on AveXis in a research note on Monday, August 28th. They issued a “reduce” rating and a $52.00 target price for the company. Zacks Investment Research lowered AveXis from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Bank of America lowered their target price on AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Canaccord Genuity started coverage on AveXis in a research note on Thursday, October 26th. They issued a “hold” rating and a $110.00 target price for the company. Finally, Wells Fargo & Company restated an “outperform” rating on shares of AveXis in a research note on Friday, September 29th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $110.67.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/05/avexis-inc-avxs-insider-sells-1420950-00-in-stock.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.